Bone marrow involvement in breast cancer. Effect on response and tolerance to combination chemotherapy

J. N. Ingle, D. C. Tormey, J. M. Bull, R. M. Simon

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Forty three patients with metastatic breast cancer who had not received prior chemotherapy were divided into two groups on the basis of whether or not a bone marrow examination revealed tumor. Both groups were treated with combination chemotherapy regimens and were analyzed with regard to response and toxicity parameters. The positive marrow group had a response rate similar to that of the negative marrow group (67% vs 71%), and a slightly shorter median time to progressive disease (240 vs 258 days) and median duration of remission (213 vs 243 days). The positive marrow group had higher requirements for hematologic support and tended to have more infectious complications. The data suggest that metastatic breast cancer patients with a bone marrow examination revealing tumor, although requiring more supportive care, may be treated as effectively with combination chemotherapy as those patients in whom the marrow examination does not reveal tumor.

Original languageEnglish (US)
Pages (from-to)104-111
Number of pages8
JournalCancer
Volume39
Issue number1
StatePublished - 1977
Externally publishedYes

Fingerprint

Combination Drug Therapy
Bone Marrow
Breast Neoplasms
Bone Marrow Examination
Neoplasms
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ingle, J. N., Tormey, D. C., Bull, J. M., & Simon, R. M. (1977). Bone marrow involvement in breast cancer. Effect on response and tolerance to combination chemotherapy. Cancer, 39(1), 104-111.

Bone marrow involvement in breast cancer. Effect on response and tolerance to combination chemotherapy. / Ingle, J. N.; Tormey, D. C.; Bull, J. M.; Simon, R. M.

In: Cancer, Vol. 39, No. 1, 1977, p. 104-111.

Research output: Contribution to journalArticle

Ingle, JN, Tormey, DC, Bull, JM & Simon, RM 1977, 'Bone marrow involvement in breast cancer. Effect on response and tolerance to combination chemotherapy', Cancer, vol. 39, no. 1, pp. 104-111.
Ingle, J. N. ; Tormey, D. C. ; Bull, J. M. ; Simon, R. M. / Bone marrow involvement in breast cancer. Effect on response and tolerance to combination chemotherapy. In: Cancer. 1977 ; Vol. 39, No. 1. pp. 104-111.
@article{59125a6c1e74486499fc72acfb879679,
title = "Bone marrow involvement in breast cancer. Effect on response and tolerance to combination chemotherapy",
abstract = "Forty three patients with metastatic breast cancer who had not received prior chemotherapy were divided into two groups on the basis of whether or not a bone marrow examination revealed tumor. Both groups were treated with combination chemotherapy regimens and were analyzed with regard to response and toxicity parameters. The positive marrow group had a response rate similar to that of the negative marrow group (67{\%} vs 71{\%}), and a slightly shorter median time to progressive disease (240 vs 258 days) and median duration of remission (213 vs 243 days). The positive marrow group had higher requirements for hematologic support and tended to have more infectious complications. The data suggest that metastatic breast cancer patients with a bone marrow examination revealing tumor, although requiring more supportive care, may be treated as effectively with combination chemotherapy as those patients in whom the marrow examination does not reveal tumor.",
author = "Ingle, {J. N.} and Tormey, {D. C.} and Bull, {J. M.} and Simon, {R. M.}",
year = "1977",
language = "English (US)",
volume = "39",
pages = "104--111",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Bone marrow involvement in breast cancer. Effect on response and tolerance to combination chemotherapy

AU - Ingle, J. N.

AU - Tormey, D. C.

AU - Bull, J. M.

AU - Simon, R. M.

PY - 1977

Y1 - 1977

N2 - Forty three patients with metastatic breast cancer who had not received prior chemotherapy were divided into two groups on the basis of whether or not a bone marrow examination revealed tumor. Both groups were treated with combination chemotherapy regimens and were analyzed with regard to response and toxicity parameters. The positive marrow group had a response rate similar to that of the negative marrow group (67% vs 71%), and a slightly shorter median time to progressive disease (240 vs 258 days) and median duration of remission (213 vs 243 days). The positive marrow group had higher requirements for hematologic support and tended to have more infectious complications. The data suggest that metastatic breast cancer patients with a bone marrow examination revealing tumor, although requiring more supportive care, may be treated as effectively with combination chemotherapy as those patients in whom the marrow examination does not reveal tumor.

AB - Forty three patients with metastatic breast cancer who had not received prior chemotherapy were divided into two groups on the basis of whether or not a bone marrow examination revealed tumor. Both groups were treated with combination chemotherapy regimens and were analyzed with regard to response and toxicity parameters. The positive marrow group had a response rate similar to that of the negative marrow group (67% vs 71%), and a slightly shorter median time to progressive disease (240 vs 258 days) and median duration of remission (213 vs 243 days). The positive marrow group had higher requirements for hematologic support and tended to have more infectious complications. The data suggest that metastatic breast cancer patients with a bone marrow examination revealing tumor, although requiring more supportive care, may be treated as effectively with combination chemotherapy as those patients in whom the marrow examination does not reveal tumor.

UR - http://www.scopus.com/inward/record.url?scp=0017331188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017331188&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 104

EP - 111

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -